Page 352 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 352
Late Breaker ePosters
LP01 DACLATASVIR PLUS SOFOSBUVIR FOR TREATMENT OF
HCV GENOTYPES 1-4 IN HIV-HCV COINFECTION: THE
ALLY-2 STUDY
David L. Wyles*, Peter Ruane, Mark S. Sulkowski, Douglas Dieterich,
Annie F. Luetkemeyer, Timothy R. Morgan, Kenneth E. Sherman,
Zhaohui Liu, Stephanie Noviello, Peter Ackerman, The United States
LP02 C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN
TREATMENT-NAIVE AND TREATMENT-EXPERIENCED
LATE BREAKER ePOSTERS PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1
INFECTION AND CHRONIC KIDNEY DISEASE
David Roth*, David Nelson, Annette Bruchfeld, Annmarie Liapakis,
Marcelo Silva, Howard Monsour Jr., Paul Martin, Stanislas Pol,
Maria-Carlota Londoño, Tarek Hassanein, Philippe Zamor,
Eli Zuckerman,Yue Zhao, Shuyan Wan, Beth Jackson,
Michael Robertson, Janice Wahl, Eliav Barr, Wayne Greaves,
The United States
LP03 SAFETY AND EFFICACY OF SHORT-DURATION
TREATMENT WITH GS-9857 COMBINED WITH
SOFOSBUVIR/GS-5816 IN TREATMENT-NAÏVE AND DAA-
EXPERIENCED GENOTYPE 1 PATIENTS WITH AND
WITHOUT CIRRHOSIS
Edward J. Gane*, Robert H. Hyland,Yin Ying, Evguenia Svarovskaia,
Luisa M. Stamm, Diana M. Brainard, G. M. Subramanian,
John G. McHutchison, Christian Schwabe, New Zealand
LP04 A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS
OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN
TREATMENT-NAÏVE OR -EXPERIENCED PATIENTS WITH
CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS:
OPTIMIST-2
Eric Lawitz*, Gary Matusow, Edwin DeJesus, Eric Yoshida,
Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert Herring,
Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas,
Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery,
Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek, The United States
352 The International Liver Congress™ 2015 • ILC Programme
LP01 DACLATASVIR PLUS SOFOSBUVIR FOR TREATMENT OF
HCV GENOTYPES 1-4 IN HIV-HCV COINFECTION: THE
ALLY-2 STUDY
David L. Wyles*, Peter Ruane, Mark S. Sulkowski, Douglas Dieterich,
Annie F. Luetkemeyer, Timothy R. Morgan, Kenneth E. Sherman,
Zhaohui Liu, Stephanie Noviello, Peter Ackerman, The United States
LP02 C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN
TREATMENT-NAIVE AND TREATMENT-EXPERIENCED
LATE BREAKER ePOSTERS PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1
INFECTION AND CHRONIC KIDNEY DISEASE
David Roth*, David Nelson, Annette Bruchfeld, Annmarie Liapakis,
Marcelo Silva, Howard Monsour Jr., Paul Martin, Stanislas Pol,
Maria-Carlota Londoño, Tarek Hassanein, Philippe Zamor,
Eli Zuckerman,Yue Zhao, Shuyan Wan, Beth Jackson,
Michael Robertson, Janice Wahl, Eliav Barr, Wayne Greaves,
The United States
LP03 SAFETY AND EFFICACY OF SHORT-DURATION
TREATMENT WITH GS-9857 COMBINED WITH
SOFOSBUVIR/GS-5816 IN TREATMENT-NAÏVE AND DAA-
EXPERIENCED GENOTYPE 1 PATIENTS WITH AND
WITHOUT CIRRHOSIS
Edward J. Gane*, Robert H. Hyland,Yin Ying, Evguenia Svarovskaia,
Luisa M. Stamm, Diana M. Brainard, G. M. Subramanian,
John G. McHutchison, Christian Schwabe, New Zealand
LP04 A PHASE 3, OPEN-LABEL, SINGLE-ARM STUDY TO
EVALUATE THE EFFICACY AND SAFETY OF 12 WEEKS
OF SIMEPREVIR (SMV) PLUS SOFOSBUVIR (SOF) IN
TREATMENT-NAÏVE OR -EXPERIENCED PATIENTS WITH
CHRONIC HCV GENOTYPE 1 INFECTION AND CIRRHOSIS:
OPTIMIST-2
Eric Lawitz*, Gary Matusow, Edwin DeJesus, Eric Yoshida,
Franco Felizarta, Reem Ghalib, Eliot Godofsky, Robert Herring,
Gary Poleynard, Aasim Sheikh, Hillel Tobias, Marcelo Kugelmas,
Ronald Kalmeijer, Monika Peeters, Oliver Lenz, Bart Fevery,
Guy De La Rosa, Jane Scott, Rekha Sinha, James Witek, The United States
352 The International Liver Congress™ 2015 • ILC Programme
